Concurrent treatment with OX40 and PD1-targeted cancer immunotherapies may be detrimental

Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice. The studies were published in Clinical Cancer...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2wLr131
via IFTTT